Company Overview and News

0
D-Street Buzz: Metals loose shine with JSPL down 6%; Jubilant Foodworks hits fresh 52-week high

2018-08-10 moneycontrol
The Indian benchmark indices continues to trade in the red this Friday afternoon, but managed to regain some lost grounds with the Sensex down 67 points at 37,956 while the Nifty shed 15 points at 11,454.
SANOFI 532617 PRMQY 533155 532778 JUBLFOOD IDBLZ 532215 CADILAHC 505200 532960 532321 AXISBANK JBLWY 500674 HEROMOTOCO EICHERMOT 509488 YESBANK EXIDEIND ECQRY HINDALCO GRAPHITE AXB IBVENTURES IBN JETAIRWAYS CANFINHOME 532648 YYBKY 511196 PEL CDLYY AXBKY 500182 HNDNF AXBA EXQDY ICICIBANK BATAINDIA 532174 HRTQY 500302 LITL 500086 500043 500440

1
Panel finds dosing mismatches in many FDCs

2018-07-26 livemint
New Delhi: The expert panel which recommended a continuation of the ban on fixed dose combinations (FDCs) has found that many FDCs were formulated without due diligence, with dosing mismatches that could result in toxicity.
SANOFI 524715 PFZ ALKEM SUNPHARMA 500674 539523 500680 PFE PFIZER

0
Sanofi India Limited - Financial Result Updates

2018-07-26 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SANOFI 500674

0
Sanofi India Limited - Record Date

2018-07-26 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SANOFI 500674

0
Sanofi India June-qtr net profit up 35% to Rs 99.6 cr

2018-07-25 moneycontrol
Drug firm Sanofi India today reported a 35.14 percent rise in its net profit to Rs 99.6 crore for the second quarter ended June 30, 2018. The company had posted a net profit of Rs 73.7 crore for the corresponding period of the previous fiscal, Sanofi India said in a filing to the BSE.
SANOFI 500674

0
Sanofi India Limited - Dividend

2018-07-25 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SANOFI 500674

0
Sanofi India Limited - Change in Director(s)

2018-07-25 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SANOFI 500674

0
Sanofi India Limited - Change in Director(s)

2018-07-25 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SANOFI 500674

0
BHEL, Canara Bank, L&T, JSW Steel results

2018-07-24 thehindubusinessline
Over 50 firms will declare their April-June quarter results on Wednesday. Among these are Ambuja Cements, BHEL, Bharat Bijlee, Bharati Infratel, Canara Bank, Chemfab Alkalies, CG Consumer, Dishman Carbogen, Gruh Finance, HCL Infosys, Hero MotoCorp, India Grid, Ind-Swift, IRB infra, JSW Steel, Jubilant Food, Jyothy Labs, Karur Vysya Bank, L&T, Omaxe, PVR, RECL, Sanofi India, Shriram City Union, SKF India, Tata Elxsi, TTK Prestiege, United Bank and Welspun Enterprises.
SANOFI 500408 500425 590003 UDBKL 500228 UBLS AMBUJACEM 511288 WELENT 532483 AMBUY UBLA SKFINDIA 500674 HEROMOTOCO 503960 500472 GRUH GRHFY JSWSTEEL CNRYY 500182 532553 BBL TATAELXSI HRTQY KARURVYSYA CANBK

0
Sanofi India Limited - Updates

2018-07-18 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SANOFI 500674

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...